{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:54:12Z","timestamp":1771656852669,"version":"3.50.1"},"reference-count":16,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"abstract":"Congenital junctional ectopic tachycardia is a rare and special type of supraventricular arrhythmia. Junctional ectopic tachycardia is characterized by persistently elevated heart rates that may cause an impairment in cardiac function. Junctional ectopic tachycardia is considered one of the most difficult-to-treat conditions even with a combination of antiarrhythmic medications. Ivabradine is a novel antiarrhythmic medication used to decrease the heart rate in adults with angina pectoris. We report a first case of a premature neonate with a normal heart structure who developed junctional ectopic tachycardia and was subsequently treated successfully with ivabradine.<\/jats:p>","DOI":"10.5863\/1551-6776-26.4.414","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T18:18:03Z","timestamp":1621448283000},"page":"414-417","source":"Crossref","is-referenced-by-count":7,"title":["Ivabradine Monotherapy for the Treatment of Congenital Junctional Ectopic Tachycardia in a Premature Neonate"],"prefix":"10.5863","volume":"26","author":[{"given":"Suzan S.","family":"Asfour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid A.","family":"Al-Omran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabeel A.","family":"Alodhaidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raneem S.","family":"Asfour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanaa M.","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mountasser M.","family":"Al-Mouqdad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"8","key":"i1551-6776-26-4-414-b1","series-title":"J Am Coll Cardiol","first-page":"690","article-title":"Pediatric nonpost-operative junctional ectopic tachycardia medical management and interventional therapies","volume":"53","year":"2009","unstructured":"Collins\n KK,\n \n \n Van Hare\n GF,\n \n \n Kertesz\n NJ,\n \n \n .\n\t\t\t\t\tPediatric nonpost-operative junctional ectopic tachycardia medical management and interventional therapies.\n\t\t\t\t\tJ Am Coll Cardiol.\n\t\t\t\t\t2009;\n\t\t\t\t\t53(\n\t\t\t\t\t8):\n\t\t\t\t\t690\u2013\n\t\t\t\t\t697."},{"issue":"5","key":"i1551-6776-26-4-414-b2","series-title":"Circulation","first-page":"1544","article-title":"Evolving concepts in the management of congenital junctional ectopic tachycardia: a multicenter study","volume":"81","year":"1990","unstructured":"Villain\n E,\n \n \n Vetter\n VL,\n \n \n Garcia\n JM,\n \n \n .\n\t\t\t\t\tEvolving concepts in the management of congenital junctional ectopic tachycardia: a multicenter study.\n\t\t\t\t\tCirculation.\n\t\t\t\t\t1990;\n\t\t\t\t\t81(\n\t\t\t\t\t5):\n\t\t\t\t\t1544\u2013\n\t\t\t\t\t1549."},{"issue":"16","key":"i1551-6776-26-4-414-b3","series-title":"Drugs","first-page":"1757","article-title":"Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease","volume":"64","year":"2004","unstructured":"DiFrancesco\n D,\n \n \n Camm\n JA.\n \n \n Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.\n\t\t\t\t\tDrugs.\n\t\t\t\t\t2004;\n\t\t\t\t\t64(\n\t\t\t\t\t16):\n\t\t\t\t\t1757\u2013\n\t\t\t\t\t1765."},{"issue":"9744","key":"i1551-6776-26-4-414-b4","series-title":"Lancet","first-page":"875","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","year":"2010","unstructured":"Swedberg\n K,\n \n \n Komajda\n M,\n \n \n Bohm\n M,\n \n \n .\n\t\t\t\t\tIvabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.\n\t\t\t\t\tLancet.\n\t\t\t\t\t2010;\n\t\t\t\t\t376(\n\t\t\t\t\t9744):\n\t\t\t\t\t875\u2013\n\t\t\t\t\t885."},{"issue":"10","key":"i1551-6776-26-4-414-b5","series-title":"J Am Coll Cardiol","first-page":"1262","article-title":"Ivabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure","volume":"70","year":"2017","unstructured":"Bonnet\n D,\n \n \n Berger\n F,\n \n \n Jokinen\n E,\n \n \n .\n\t\t\t\t\tIvabradine in children with dilated cardiomyopathy and symptomatic chronic heart failure.\n\t\t\t\t\tJ Am Coll Cardiol.\n\t\t\t\t\t2017;\n\t\t\t\t\t70(\n\t\t\t\t\t10):\n\t\t\t\t\t1262\u2013\n\t\t\t\t\t1272."},{"issue":"13","key":"i1551-6776-26-4-414-b6","series-title":"J Am Coll Cardiol","first-page":"774","article-title":"Ivabradine in the paediatric population: Preliminary findings","volume":"67","year":"2016","unstructured":"Donne\n GD,\n \n \n Roses-Noguer\n F,\n \n \n Till\n J,\n \n \n .\n\t\t\t\t\tIvabradine in the paediatric population: Preliminary findings.\n\t\t\t\t\tJ Am Coll Cardiol.\n\t\t\t\t\t2016;\n\t\t\t\t\t67(\n\t\t\t\t\t13):\n\t\t\t\t\t774."},{"issue":"6","key":"i1551-6776-26-4-414-b7","series-title":"HeartRhythm Case Rep","first-page":"333","article-title":"Ivabradine for treatment of tachyarrhythmias in children and young adults","volume":"5","year":"2019","unstructured":"Janson\n CM,\n \n \n Tan\n RB,\n \n \n Iyer\n VR,\n \n \n .\n\t\t\t\t\tIvabradine for treatment of tachyarrhythmias in children and young adults.\n\t\t\t\t\tHeartRhythm Case Rep.\n\t\t\t\t\t2019;\n\t\t\t\t\t5(\n\t\t\t\t\t6):\n\t\t\t\t\t333\u2013\n\t\t\t\t\t337."},{"issue":"2","key":"i1551-6776-26-4-414-b8","series-title":"Am J Cardiol","first-page":"298","article-title":"Junctional ectopic tachycardia in children: electrocardiography, electrophysiology and pharmacologic response","volume":"44","year":"1979","unstructured":"Garson\n A\n Jr\n ,\n\t\t\t\t\t\tGillettePC.\n Junctional ectopic tachycardia in children: electrocardiography, electrophysiology and pharmacologic response.\n\t\t\t\t\tAm J Cardiol.\n\t\t\t\t\t1979;\n\t\t\t\t\t44(\n\t\t\t\t\t2):\n\t\t\t\t\t298\u2013\n\t\t\t\t\t302."},{"issue":"1","key":"i1551-6776-26-4-414-b9","series-title":"Eur J Cardiothorac Surg","first-page":"75","article-title":"Junctional ectopic tachycardia after surgery for congenital heart disease: incidence, risk factors and outcome","volume":"39","year":"2011","unstructured":"Mildh\n L,\n \n \n Hiippala\n A,\n \n \n Rautiainen\n P,\n \n \n .\n\t\t\t\t\tJunctional ectopic tachycardia after surgery for congenital heart disease: incidence, risk factors and outcome.\n\t\t\t\t\tEur J Cardiothorac Surg.\n\t\t\t\t\t2011;\n\t\t\t\t\t39(\n\t\t\t\t\t1):\n\t\t\t\t\t75\u2013\n\t\t\t\t\t80."},{"key":"i1551-6776-26-4-414-b10","series-title":"Drug Des Devel Ther","first-page":"689","article-title":"Ivabradine, coronary artery disease, and heart failure: beyond rhythm control","volume":"8","year":"2014","unstructured":"Scicchitano\n P,\n \n \n Cortese\n F,\n \n \n Ricci\n G,\n \n \n .\n\t\t\t\t\tIvabradine, coronary artery disease, and heart failure: beyond rhythm control.\n\t\t\t\t\tDrug Des Devel Ther.\n\t\t\t\t\t2014;\n\t\t\t\t\t8:\n\t\t\t\t\t689\u2013\n\t\t\t\t\t700."},{"issue":"6","key":"i1551-6776-26-4-414-b11","series-title":"Heart Rhythm","first-page":"1297","article-title":"Adjunctive ivabradine in combination with amiodarone: A novel therapy for pediatric congenital junctional ectopic tachycardia","volume":"13","year":"2016","unstructured":"Dieks\n JK,\n \n \n Klehs\n S,\n \n \n Muller\n MJ,\n \n \n .\n\t\t\t\t\tAdjunctive ivabradine in combination with amiodarone: A novel therapy for pediatric congenital junctional ectopic tachycardia.\n\t\t\t\t\tHeart Rhythm.\n\t\t\t\t\t2016;\n\t\t\t\t\t13(\n\t\t\t\t\t6):\n\t\t\t\t\t1297\u2013\n\t\t\t\t\t1302."},{"issue":"7","key":"i1551-6776-26-4-414-b12","series-title":"J Cardiovasc Electrophysiol","first-page":"822","article-title":"Potential new indication for ivabradine: treatment of a patient with congenital junctional ectopic tachycardia","volume":"24","year":"2013","unstructured":"Al-Ghamdi\n S,\n \n \n Al-Fayyadh\n MI,\n \n \n Hamilton\n RM.\n \n \n Potential new indication for ivabradine: treatment of a patient with congenital junctional ectopic tachycardia.\n\t\t\t\t\tJ Cardiovasc Electrophysiol.\n\t\t\t\t\t2013;\n\t\t\t\t\t24(\n\t\t\t\t\t7):\n\t\t\t\t\t822\u2013\n\t\t\t\t\t824."},{"issue":"10","key":"i1551-6776-26-4-414-b13","series-title":"Pacing Clin Electrophysiol","first-page":"1372","article-title":"Ivabradine is an effective antiarrhythmic therapy for congenital junctional ectopic tachycardia-induced cardiomyopathy during infancy: case studies","volume":"41","year":"2018","unstructured":"Ergul\n Y,\n \n \n Ozturk\n E,\n \n \n Ozgur\n S,\n \n \n .\n\t\t\t\t\tIvabradine is an effective antiarrhythmic therapy for congenital junctional ectopic tachycardia-induced cardiomyopathy during infancy: case studies.\n\t\t\t\t\tPacing Clin Electrophysiol.\n\t\t\t\t\t2018;\n\t\t\t\t\t41(\n\t\t\t\t\t10):\n\t\t\t\t\t1372\u2013\n\t\t\t\t\t1377."},{"key":"i1551-6776-26-4-414-b14","article-title":"Corlanor [package insert]","year":"2015","unstructured":"Corlanor [package insert].\n\t\t\t\t\tThousand Oaks, CA:\n\t\t\t\t\tAmgen Inc;\n\t\t\t\t\t2015."},{"issue":"3 suppl","key":"i1551-6776-26-4-414-b15","series-title":"J Allergy Clin Immunol","first-page":"S128","article-title":"Impact of developmental pharmacology on pediatric study design: overcoming the challenges","volume":"106","year":"2000","unstructured":"Kearns\n GL.\n \n \n Impact of developmental pharmacology on pediatric study design: overcoming the challenges.\n\t\t\t\t\tJ Allergy Clin Immunol.\n\t\t\t\t\t2000;\n\t\t\t\t\t106(\n\t\t\t\t\t3 suppl):\n\t\t\t\t\tS128\u2013\n\t\t\t\t\tS138."},{"issue":"39","key":"i1551-6776-26-4-414-b16","series-title":"PW Drug Interact Newsl","first-page":"1","article-title":"What is the process to determine if medications are to be classified as weak, moderate or strong inhibitors of CYP3A4?","volume":"1","year":"2009","unstructured":"Busti\n AJ,\n \n \n Herrington\n JD,\n \n \n Daves\n BJ,\n \n \n McKeever\n GC.\n \n \n What is the process to determine if medications are to be classified as weak, moderate or strong inhibitors of CYP3A4?\n \n PW Drug Interact Newsl\n .\n\t\t\t\t\t2009;\n\t\t\t\t\t1(\n\t\t\t\t\t39):\n\t\t\t\t\t1\u2013\n\t\t\t\t\t3"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/26\/4\/article-p414.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/26\/4\/414\/2830016\/i1551-6776-26-4-414.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/26\/4\/article-p414.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/26\/4\/article-p414.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:44:51Z","timestamp":1747356291000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/26\/4\/article-p414.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":16,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-26.4.414","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}